Inhibiční účinky nemethylovaných CpG oligodeoxynukleotidů na MHC I+ a MHC I- nádory vyvolané HPV16

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F06%3A00024481" target="_blank" >RIV/68378050:_____/06:00024481 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and -proficient HPV16-associated tumours

Popis výsledku v původním jazyce

Unmethylated oligodeoxynucleotides containing guanine-cytidine dimers (CpG ODN) were described as potent inducers of selected antitumour immune responses and the immunotherapeutic efficacy of CpG ODN has been examined either alone or as a vaccine adjuvant. We hypothesized that CpG ODN therapy could be effective in immunotherapy of conventional MHC class I+ tumours as well as tumours that lost MHC class I expression during their progression. We employed the animal model resembling MHC class I+ and I- human papilloma virus 16-associated tumours. Immunotherapy with CpG ODN 1826 significantly reduced the growth of MHC class I-proficient and -deficient tumours. We also demonstrated that CpG ODN 1585, which indirectly activate natural killer cells, induced regression of MHC class I- tumours but not I+ tumours. This infers that synthetic CpG ODN have a potential for therapy of MHC class I+ and I- tumours and thus could be also used against tumours with down-regulated MHC class I expression.

Název v anglickém jazyce

Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and -proficient HPV16-associated tumours

Popis výsledku anglicky

Unmethylated oligodeoxynucleotides containing guanine-cytidine dimers (CpG ODN) were described as potent inducers of selected antitumour immune responses and the immunotherapeutic efficacy of CpG ODN has been examined either alone or as a vaccine adjuvant. We hypothesized that CpG ODN therapy could be effective in immunotherapy of conventional MHC class I+ tumours as well as tumours that lost MHC class I expression during their progression. We employed the animal model resembling MHC class I+ and I- human papilloma virus 16-associated tumours. Immunotherapy with CpG ODN 1826 significantly reduced the growth of MHC class I-proficient and -deficient tumours. We also demonstrated that CpG ODN 1585, which indirectly activate natural killer cells, induced regression of MHC class I- tumours but not I+ tumours. This infers that synthetic CpG ODN have a potential for therapy of MHC class I+ and I- tumours and thus could be also used against tumours with down-regulated MHC class I expression.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EC - Imunologie

OECD FORD obor

—

Projekt

<a href="/cs/project/GA301%2F04%2F0492" target="_blank" >GA301/04/0492: Imunoterapie MHC I negativních nádorů: modulace exprese MHC I demethylací a výběr vhodných adjuvans</a><br>

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2006

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Cancer

ISSN

0020-7136

e-ISSN

—

Svazek periodika

118

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

12

Strana od-do

1836-1842

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—